CSIMarket
 
In8bio Inc   (INAB)
Other Ticker:  
 
 
Price: $1.1400 $-0.02 -1.724%
Day's High: $1.2527 Week Perf: -10.24 %
Day's Low: $ 1.14 30 Day Perf: 1.79 %
Volume (M): 326 52 Wk High: $ 3.95
Volume (M$): $ 372 52 Wk Avg: $1.41
Open: $1.18 52 Wk Low: $0.65



 Market Capitalization (Millions $) 36
 Shares Outstanding (Millions) 32
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 4

In8bio Inc
In8bio Inc is a biotechnology company that specializes in the development of innovative and targeted cell therapies for the treatment of cancer and other diseases. The company focuses on utilizing its proprietary technologies and expertise to engineer T cells, which are important immune cells, to recognize and kill specific cancer cells. In8bio's approach aims to improve the effectiveness and safety of cell therapies, potentially offering better treatment options for patients. The company is dedicated to advancing the field of cell therapy and bringing novel therapies to market to address unmet medical needs.


   Company Address: 350 5th Avenue New York 10118 NY
   Company Phone Number: 600-6438   Stock Exchange / Ticker: NASDAQ INAB
   INAB is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Novel Gamma-Delta T Cell Therapy Shows Promise for Glioblastoma Patients: IN8bio Inc.'s Potential Game-Changer

Published Wed, Feb 14 2024 1:00 PM UTC

Glioblastoma, a highly aggressive form of brain cancer, has long been a challenging condition to treat effectively. However, there is new hope on the horizon as IN8bio, Inc. announces a groundbreaking gamma-delta T cell therapy for glioblastoma. Published in Frontiers in Immunology, this peer-reviewed article discusses the current strategy and future direction of this unique...

Clinical Study

IN8bio's Bold Future: A Look at Pioneering Accomplishments & Ambitious Goals Towards Cancer-Free Survival

Published Thu, Jan 4 2024 1:02 PM UTC

Over the past few years, IN8bio, Inc. (NASDAQ: INAB), a commendable trailblazer in the clinical-stage biopharmaceutical landscape, has made significant strides in developing innovative gamma-delta T-cell therapies. The biopharmaceutical company recently took a magnifying glass to its past accomplishments, breathed life into its present initiatives, and presented an alluring ...

Clinical Study

IN8bio to Host Investor Call to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

Published Tue, Dec 5 2023 1:01 PM UTC


IN8bio, a leading clinical-stage biopharmaceutical company specializing in innovative gamma-delta T cell therapies, has announced that it will be hosting a conference call on Tuesday, December 12, 2023, at 8:30 am ET. The purpose of the call is to discuss the updated clinical data from the Phase 1 trial of their product, INB-100, in patients with leukemia. This data wil...

Clinical Study

IN8bios INB-200 Shows Unprecedented Glimmer of Hope in Glioblastoma Treatment: Extended Progression-Free Survival Offers New Lease on Life

Published Mon, Nov 20 2023 12:00 PM UTC

IN8bios INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
Glioblastoma (GBM) is an aggressive form of brain cancer with an incredibly poor prognosis. It is the most common malignant brain tumor in adults and is notoriously difficult to treat. However, a breakthrough has emerged in the form of an experimental drug known ...

In8bio Inc

In8bio Inc Surprises Investors with a Game-Changing Turnaround, Generating Significant Revenue Growth in Q3 2023

In a surprising twist, the recent earnings season for IN8bio Inc (INAB) did not present any modifications to the company's revenue between July and September 30, 2023. Contrary to investor expectations, there were no significant changes in this aspect. However, shareholders are closely monitoring the company's operating loss, which stood at $-7.169 million during the same period. Despite these figures, there is some optimism as IN8bio Inc seems to be conducting its business more economically compared to the previous fiscal year, which ended on September 30, 2022, with an operating loss of $-7.399 million.
The encouraging news is that the organization has managed to decrease its diminishing returns. In the third quarter of 2022, the company experienced a loss of $-7.399 million, but in the corresponding period of 2023, the loss decreased slightly to $-7.169 million. This improvement bodes well for IN8bio Inc's ambition to establish itself as a prominent leader in the Healthcare sector.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com